A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT00883116 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
551
Enrollment
INDUSTRY
Sponsor class

Stopped Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.

Conditions

Interventions

Sponsor

R-Pharm